1
|
Iwawaki Y, Mizusawa N, Iwata T, Higaki N, Goto T, Watanabe M, Tomotake Y, Ichikawa T, Yoshimoto K. MiR-494-3p induced by compressive force inhibits cell proliferation in MC3T3-E1 cells. J Biosci Bioeng 2015; 120:456-62. [PMID: 25795570 DOI: 10.1016/j.jbiosc.2015.02.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2014] [Revised: 01/28/2015] [Accepted: 02/06/2015] [Indexed: 12/01/2022]
Abstract
Mechanical stimuli regulate fundamental cell processes such as proliferation, differentiation, and morphogenesis. We attempted to identify microRNA (miRNA) whose expression is changed during compressive treatment in MC3T3-E1, a pre-osteoblastic cell line. Microarray analysis followed by reverse transcription-quantitative polymerase chain reaction revealed that compressive force at 294 Pa for 24 h in MC3T3-E1 cells increased levels of miR-494-3p, miR-146a-5p, miR-210-3p, and miR-1247-3p. Among these miRNAs, miR-494-3p was found to inhibit cell proliferation in MC3T3-E1 cells. Furthermore, cells subjected to compressive force showed slower cell growth compared with control cells. Levels of mRNA for fibroblast growth factor receptor 2 (FGFR2) and Rho-associated coiled-coil kinase 1 (ROCK1), which were predicted to be targets of miR-494-3p, were decreased by compressive force or overexpression of miR-494-3p mimics in MC3T3-E1 cells. Furthermore, binding sites of miR-494-3p within 3'-untranslated regions of Fgfr2 and Rock1 were determined using luciferase reporter assay. In conclusion, compressive force affected expressions of several miRNAs including miR-494-3p in MC3T3-E1 cells. Compressive force might inhibit cell proliferation in osteoblasts by up-regulating miR-494-3p followed by FGFR2 and ROCK1 gene repressions.
Collapse
Affiliation(s)
- Yuki Iwawaki
- Department of Oral and Maxillofacial Prosthodontics, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Noriko Mizusawa
- Department of Medical Pharmacology, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Takeo Iwata
- Department of Medical Pharmacology, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Nobuaki Higaki
- Department of Oral and Maxillofacial Prosthodontics, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Takaharu Goto
- Department of Oral and Maxillofacial Prosthodontics, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Megumi Watanabe
- Department of Oral and Maxillofacial Prosthodontics, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Yoritoki Tomotake
- Oral Implant Center, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Tetsuo Ichikawa
- Department of Oral and Maxillofacial Prosthodontics, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| | - Katsuhiko Yoshimoto
- Department of Medical Pharmacology, Institute of Health Biosciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima City 770-8504, Japan.
| |
Collapse
|